- Kymera Therapeutics Inc KYMR announced clinical results from the patient cohort portion of its KT-474 (IRAK4) Phase 1 trial in hidradenitis suppurativa (HS) and atopic dermatitis (AD) patients.
- KT-474 demonstrated robust IRAK4 knockdown in blood and active skin lesions and systemic suppression of proinflammatory cytokines and chemokines with a favorable safety profile.
- KT-474 showed IRAK4 knockdown in blood and skin comparable to MAD3, with maximum degradation exceeding 90%. Target degradation was similar across HS and AD patients in blood and skin.
- In ex vivo cytokine stimulation assays, KT-474 demonstrated broad and deep inhibition of multiple disease-relevant cytokines, including inhibition of up to 84% in HS and up to 98% in AD.
- KT-474 also reduced several circulating cytokines and acute phase reactants in vivo.
- Sanofi SNY, collaborating with Kymera on developing KT-474 (SAR444656) outside of the oncology and immune-oncology fields, has notified Kymera of its commitment to advance KT-474 into Phase 2 clinical studies.
- The initial Phase 2 trial of KT-474 will investigate its potential in HS and AD, with the first study initiating in 2023.
- Price Action: KYMR shares are up 22.2% at $31.57 on the last check Wednesday.
- Photo Via Company
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
